Who is sponsoring NCT06082947?

NCT06082947 is sponsored by Nationwide Children's Hospital.

What drugs are being tested in NCT06082947?

Interventions in NCT06082947: CliniMACS®.

What condition does NCT06082947 study?

NCT06082947 studies Hematopoietic Stem Cell Transplantation, Hematologic Malignancy.

Is NCT06082947 still recruiting?

NCT06082947 is currently recruiting now. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT06082947: TB19DHCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)

Recruiting now NA Last updated 2 April 2025

What this trial tests

NA trial testing CliniMACS® in Hematopoietic Stem Cell Transplantation in 50 participants. Currently enrolling.

Timeline

18 December 2023

Primary endpoint
1 December 2028

1 December 2030

Quick facts

Lead sponsor	Nationwide Children's Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	18 December 2023
Primary completion	1 December 2028
Estimated completion	1 December 2030
Sites	1 location across United States

Drugs / interventions tested

CliniMACS®

Conditions studied

Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →
Hematologic Malignancy — all drugs for Hematologic Malignancy →

Sponsor

Nationwide Children's Hospital

Who can join

Under 30, any sex, with Hematopoietic Stem Cell Transplantation or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT). Patients will receive an allogenic HSCT from a matched unrelated donor (MUD), mismatch unrelated donor (MMUD) or a mismatched related (haploidentical) donor. Patients will receive a granulocyte-colony stimulating factor (G-CSF) ± Plerixafor donor mobilized peripheral stem cell donor transplant following CliniMACS® αβT cell/CD19+B cell depletion. Cluster of Differentiation 34 (CD34) and αβT cell content of the graft is determined based on the transplant indication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting

Other Nationwide Children's Hospital trials

Trials by the same sponsor.

NCT07435792 — TetraGraph to Evaluate Onset and Recovery Times of Rocuronium · NA · not yet recruiting
NCT07026942 — Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML · Phase 1, PHASE2 · not yet recruiting
NCT06795126 — Little NIRVANA for Pediatric Pain and Anxiety · NA · enrolling by invitation
NCT06854991 — Healthy Children and Virtual Reality Mediation of Simulated Pain · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06082947 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nationwide Children's Hospital
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06082947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing